the occurrence of sudden cardiac death, suggesting a proarrhythmic effect of aldosterone. Arrhythmia provoked by aldosterone has been demonstrated in dogs after myocardial infarction. 15 The available information on the cellular and molecular mechanisms for the potential proarrhythmic action of aldosterone is still limited, and much remains to be clarified. Aldosterone affects Na + transport in the cardiac cell membrane through upregulation of the Na + /K + ATPase α1 subunit. 16 Short-term exposure of cardiac myocytes to aldosterone has been shown to increase Na + influx via the Na + -K + -Clcotransport and the Na + /K + pump. 17 Aldosterone increases the L-type Ca 2+ current in adult rat ventricular myocytes, and increases the fast Na + current in adult mouse ventricular myocytes. [18] [19] [20] More recently, aldosterone was shown to increase L-type and T-type Ca 2+ currents in rat ventricular myocytes following the stimulation of gene expression. 21 In cultured neonatal rat ventricular myocytes, Muto et al reported that exposure to aldosterone at a low concentration (10 -8 mol/L) resulted in an increase of hyperpolarization-activated current in association with upregulation of mRNA and protein for HCN2 and HCN4, whereas exposure to aldosterone at a higher concentration (10 -6 mol/L) resulted in opposite effects. 22 Ouvrand-Pascaud et al reported that transgenic mice with cardiac-specific MR overexpression display prolonged ventricular repolarization and lethal arrhythmia in association with a decreased transient outward K + current and increased L-type Ca 2+ current. 23 The principal gap junction protein expressed in mammalian heart ventricles is connexin (Cx) 43 . Cx40 is abundant in atrial tissue and in the atrioventricular conduction system, (Received November 14, 2008 ; revised manuscript received March 11, and Cx45 is observed in the sinoatrial and atrioventricular nodes. [24] [25] [26] Remodeling of gap junctions in the heart is an important feature of the structural substrates for conduction disturbance and arrhythmogenesis under various pathological conditions including myocardial ischemia, infarction and hypertrophy. [25] [26] [27] In a previous study using neonatal rat cultured ventricular myocytes, we showed that rapid electrical stimulation causes upregulation of Cx43 and a concomitant increase in conduction velocity (CV), mainly through an autocrine effect of angiotensin II (Ang II) that activates extracellular signal-regulated protein kinases (ERKs) and p38 mitogenactivated protein kinases (MAPKs). 28 Aldosterone, which is downstream of the RAAS, could also have a direct action on the Cx43 expression of ventricular myocytes. The present study was designed to test this hypothesis.
Methods
All animals were handled according to the guideline of the Animal Care Committee of Yamaguchi University. This investigation complied with the "Guide for the Care and Use of Laboratory Animals" published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996) .
Cell Culture
Primary cultures of 1-to 2-day-old neonatal rat ventricular myocytes were prepared as reported previously. 28, 29 Myocytes that were dissociated enzymatically were seeded on culture trays at a concentration of 3×10 5 cells/cm 2 , and then incubated in Leibovitz L-15 Medium (Worthington Biochemical Co, Lakewood, NJ, USA) supplemented with 5% fetal bovine serum at 37°C. The cell suspension was replated to reduce the fibroblast content. Cells were grown in a random orientation (isotropic growth) to make a confluent layer, and by day 5 exhibited synchronized spontaneous beating with a regular frequency. The relative population of myocytes over non-myocytes in the respective culture, which was estimated by immunolabeling against with an anti-actin antibody, was >97%. Cultured myocytes on day 5 were transferred to serum-free medium, and exposed to aldosterone (10 -8 -10 -4 mol/L, Sigma, St Louis, MO, USA) for 24 h. To determine the expression of phosphorylated or nonphosphorylated Cx43, the cultured myocytes on day 5 were treated with either protein kinase A (PKA) inhibitor (H-8 (N-[2-(methylamino) ethyl]-5-isoquinolinesulfonamide dihydrochloride; Biaffin GmbH & Co KG, Kassel, Germany) 30 or protein kinase C (PKC) inhibitor (Chelerythrine; Calbiochem, Tokyo, Japan) 31 during exposure to 10 -8 mol/L aldosterone. In experiments to elucidate the signaling cascade, the cultured myocytes on day 5 were pretreated for 1 h with a MR antagonist, eplerenone (10 -6 mol/L and 10 -5 mol/L; Pfizer Japan, Tokyo), 32 a glucocorticoid receptor (GR) antagonist, mifepristone (10 -6 mol/L and and 10 -5 mol/L; Sigma) 33 or Ang II type 1 receptor antagonist, losartan (10 -7 mol/L; Merck, Rahway, NJ, USA) 28 before the addition of aldosterone. 34 
Electrophoresis and Immunoblotting
Collected cells were lysed and the cellular extracts electrophoresed on SDS-polyacrylamide gels as previously described. 28 Rabbit polyclonal anti-Cx43 antibody (1:1,000, Zymed, South San Francisco, CA, USA), rabbit polyclonal anti-Cx40 antibody (1:1,000; Alpha Diagnostic, San Antonio, TX, USA), monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (1:5,000; Clone GAPDH-71.7; Sigma), rabbit anti-ERK1/2 antibody, rabbit anti-c-Jun NH2-terminal kinase (JNK)1 antibody, rabbit anti-p38 antibody (1:1,000; Santa Cruz, CA, USA), rabbit anti-active ® MAPK pAb, rabbit anti-active ® JNK pAb, and rabbit antiactive ® p38 pAb (1:2,000; Promega, WI, USA) were used as the primary antibodies. The amount of protein recognized by the antibodies was quantified by means of an ECL™ immunoblotting detection system (Amersham, Buckinghamshire, UK).
Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from cultured myocytes using an RNAqueous Kit (Ambion, Austin, TX), and a real-time RT-PCR assay (Perkin-Elmer ABI Prism 7700) was performed to quantify the mRNA expression of Cx43. 28, 35 GAPDH mRNA was used as an internal control. The sequences of the PCR primers and sequence-specific probes are shown in Table. Immunohistochemistry For immunodetection of gap junctions, a polyclonal rabbit anti-Cx43 antibody (Zymed) was used. After permeabilization (0.1% Triton X-100), quenching and blocking (10% goat serum), samples were incubated with the antibody (1:100 diluted in phosphate-buffered saline) overnight at room temperature. Primary antibody-bound Cx43 was visualized by FITC-conjugated anti-rabbit IgG, and examined under a confocal microscope (LSM500, Zeiss, Germany). Samples processed without the primary antibody served as negative controls. The proportion of the Cx43 immunoreactive signal was defined as the number of high-signal-intensity (>90 % of the maximum level) pixels divided by the total number of pixels occupied by the myocytes. 36 Ten individual measurements in different fields were averaged to yield a single value for each culture slide.
Extracellular Potential Mapping of Propagation
The conduction properties of the cultured ventricular myo- cytes were examined by extracellular potential mapping using a specifically designed multielectrode array system (MED-P545A and MED64, Panasonic, Tokyo, Japan). 28, 37, 38 The 64-planar microelectrodes, each 50×50 μm, were arranged in an 8×8 pattern with an inter-electrode distance of 450 μm to cover 3,150×3,150 μm beneath the cultured myocytes. All 64 unipolar signals were recorded simultaneously with a common reference from 4 distant electrodes, and amplified with high gain (60 dB) and at a low frequency (1.0-100 Hz) filter setting. Constant stimuli at 3.0 Hz were applied via 4 lateral electrodes of the recording array to elicit 1-way propagation of excitation in the observation area. Biphasic pulses of 0.1 ms duration were used for the stimulation with an intensity of 100-200 μA (twice the diastolic threshold). Activation time at each recording site was identified by a sharp negative deflection. The CV was measured by plotting the activation time against distance from the stimulation site along a midline from right to left.
Statistical Analysis
All data are presented as the mean ± standard error. Statistical analysis was performed using analysis of variance followed by multiple comparisons using Fisher's protected least-significant difference and unpaired Student's t-test. Differences were taken to be significant at P<0.05. (Figure 1E) . On the other hand, 10 -6 and 10 -4 mol/L aldosterone, which are the concentrations reported to induce myocyte apoptosis, 39 significantly decreased the amount of Cx43 protein (0.31±0.06 and 0.25±0.03 at 24 h, respectively, n=5 each, P< 0.01 vs 0 h) (Figure 2A) . Interestingly, 10 -6 and 10 -4 mol/L aldosterone did not affect the expression of Cx43 mRNA (0.82±0.09 and 1.15±0.03 at 24 h, respectively, n=5 each) ( Figure 2B) .
Results

Aldosterone Regulates Cx43 Expression in a Dose-Dependent Manner
For Cx40, the amount of protein normalized to control (GAPDH) revealed no significant difference after treatment for 24 h with 10 -8 -10 -4 mol/L aldosterone (Figures 1A,2C) . (A) Cx43 protein levels estimated by western blotting analysis. The Cx43 protein amount was normalized to GAPDH (mean ± SE; n=5 in each group). (B) Cx43 mRNA levels estimated by real-time reverse transcription-polymerase chain reaction. The Cx43 mRNA amount was normalized to GAPDH (mean ± SE; n=5 in each group). (C) Cx40 protein levels estimated by western blotting analysis. The Cx40 protein amount was normalized to GAPDH (mean ± SE; n=5 in each group).**P<0.01 vs 0 h. All data normalized to the value of 0 h, which was set at 1. Cx, connexin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, not significant.
Circulation Journal Vol.73, August 2009
Pharmacological Evidence for MR Involvement in Aldosterone-Dependent Upregulation of Cx43 Most biological actions of aldosterone are mediated by its binding to intracellular MR, which, once activated, modulate gene expression. 4 To study the role of MR in aldosterone-induced alterations in Cx43 expression, we investigated the effects of an MR blocker, eplerenone, added to the culture medium. The 10 -8 mol/L aldosterone-induced increase in Cx43 protein expression (1.52±0.10 at 24 h, n=6) was significantly blocked by 10 -6 M eplerenone (1.01±0.20 at 24 h, n=4, P<0.01), as shown in Figure 3 . Because aldosterone may also bind to the GR, 40 we investigated the action of aldosterone in ventricular myocytes co-incubated with mifepristone, a GR antagonist. As shown in Figure 3 , 10 -6 mol/L Figure 3 . Quantitative analysis of Cx43 protein levels in cardiomyocytes exposed to 10 -8 mol/L aldosterone in the presence or absence of blockers: mineralocorticoid blocker, eplerenone; glucocorticoid blocker, mifepristone; angiotensin II type 1 blocker, losartan. The Cx43 protein amount was normalized to GAPDH (mean ± SE; n=4-6 in each group). *P<0.05, **P<0.01 vs 0 h. All data normalized to the value of a 0 h, which was set at 1. Cx, connexin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, not significant. mifepristone did not block the 10 -8 mol/L aldosteroneinduced upregulation of Cx43. Losartan also did not affect the alterations in Cx43 expression caused by exposure to 10 -8 mol/L aldosterone (Figure 3) . Eplerenone, mifepristone, and losartan did not block the 10 -4 mol/L aldosterone-dependent downregulation of Cx43 (data not shown). These results indicate that aldosterone-induced upregulation of Cx43 expression is mediated by the MR.
Effects of Aldosterone on ERK, JNK, and p38 MAPK Signaling Pathways
We next examined the effects of aldosterone on 3 major MAPK signaling pathways. Although the total level of ERK was unaffected, phosphorylated ERK (p-ERK) showed a significant increase in response to 10 -8 mol/L aldosterone, with a peak at 15 min (by 1.8±0.4-fold, P<0.05) (Figure 4A ). For JNK, the total level was also unchanged, but phos- phorylated JNK (p-JNK) showed a significant increase in response to 10 -8 mol/L aldosterone, with a peak at 30 min (by 3.1±1.2-fold, P<0.05) (Figure 4B ). For p-38 MAPKs (p-38), although phosphorylated p-38 (p-p38) at 15 min after exposure tended to be increased (by 1.3±0.2-fold, P=0.09), the total p-38 and p-p38 levels showed no significant changes in response to 10 -8 mol/L aldosterone. These results suggest that MAPK, and especially ERK and JNK signaling pathways, are activated by 10 -8 mol/L aldosterone.
Aldosterone Modulates Electrophysiological Characteristics in Ventricular Myocytes
We investigated the functional manifestation of aldosterone-induced alterations in Cx43 expression by multi-electrode extracellular potential mapping. The measurements were made before and after treatment with 10 -8 -10 -4 mol/L aldosterone. A clear local electrogram composed of a positive deflection followed by negative deflection was recorded from most (>90%) of the 64 electrodes ( Figure 5A) . Isochrone maps of the activation time showed an almost uniform propagation of excitation from right to left both before (control, Figure 5B ) and after exposure to 10 -8 mol/L and 10 -6 mol/L aldosterone for 24 h (Figures 5C,D) . The activation times after treatment with 10 -8 mol/L aldosterone at the respective recording sites were much shorter than those of the control, indicating 10 -8 mol/L aldosterone-induced acceleration of propagation. Such changes in propagation following exposure to 10 -8 mol/L aldosterone were prevented by pretreatment with 10 -6 mol/L eplerenone ( Figure 5E ). Figure 6 shows the pooled data for CV. In the absence of eplerenone, the CV was increased by 10 -8 mol/L aldosterone; the value after 24 h treatment with 10 -8 mol/L aldosterone (25.6±0.5 cm/s, n=7) was significantly higher than the control (0 h) (20.7±1.2 cm/s, n=5). In the presence of eplerenone, 10 -8 mol/L aldosterone did not affect CV; the value at 24 h (22.7±0.7 cm/s, n=7) was not significantly different from the control (0 h). Moreover, 10 -6 mol/L mifepristone did not prevent the 10 -8 mol/L aldosterone-induced increase in CV (24.1±1.3 cm/s, n=6). The 10 -6 and 10 -4 mol/L aldosterone significantly decreased the CV (18.0±0.8 cm/s and 15.5±0.5 cm/s, respectively, n=5 each, P<0.05) compared with the control (0 h) (Figure 6 ). Eplerenone and mifepristone did not prevent the 10 -6 and 10 -4 mol/L aldosteroneinduced decrease in CV (data not shown).
Discussion
In the present study, we have shown that aldosterone may be involved in arrhythmogenic gap junction remodeling through its dual effects on the expression of Cx43: upregulation at low concentrations, which is mediated at least in part by MR stimulation, and downregulation at higher concentrations. Indeed, 10 -8 mol/L aldosterone specifically upregulated Cx43 expression through MR regulation, and at least in part by PKC-MAPKs, and accelerated the propagation of excitation in ventricular myocytes. This conclusion is supported by the finding that incubation of cells with 10 -8 mol/L aldosterone for 24 h increased Cx43 expression (mRNA and protein), and this increase was prevented by the MR antagonist, eplerenone. Treatment of the myocytes with aldosterone at 10 -6 -10 -4 mol/L downregulated Cx43 with a decrease in CV, which was not prevented by the MR antagonist. These results are potentially of interest, considering the role of the MR in cardiac derangements, including sudden arrhythmic death under pathological conditions.
Regulation of Cardiac Gap Junction Cx43 by Aldosterone
Aldosterone, as with other steroid hormones, initiates its effects by binding to intracellular receptors, which are then able to control the transcription of a number of genes. For instance, aldosterone is reported to regulate the Ca 2+ channel, Ito, If, and Na + -K + ATPase through its genomic effects. 16, [18] [19] [20] 22 To our knowledge, this is the first time that an aldosterone-induced functional expression of Cx43 has been reported. It has been shown that a MR-hormone complex can activate transcription of a target gene by binding an upstream transcription regulatory element. 41 Indeed, in the rat cardiac Cx43 gene the promoter region preceding the first exon contains a half-site for hormone response elements (HRE), which might bind the MR, with a consensus 15-nucleotide sequence of AGAACAnnnTGTTCT. 42 In the present study, the expression of Cx43 (mRNA and protein) was upregulated by 10 -8 mol/L aldosterone exposure for 24 h, and the upregulation of Cx43 might be caused by its genomic effect through the MR.
On the other hand, it is also reported that the growth response induced by aldosterone is not only dependent on the MR, but is also associated with the activation of ERK, JNK, and PKC-α. 43 It has been reported that cardiac Cx43 expression is regulated by the MAPK family, including ERK, JNK, and p38 MAPKs. 28, 44, 45 In this study, we also investigated the effect of aldosterone-induced activated MAPK signaling pathways, and our results showed that aldosterone activates the ERK and JNK signaling pathways. In addition, the PKC inhibitor attenuated the 10 -8 mol/L aldosterone-induced upregulation of Cx43 expression. These results indicate that the PKC-MAPKs pathway, at least in part, contributed to the upregulation of Cx43 expression in our system. Interestingly, in this study 10 -6 -10 -4 mol/L aldosterone, which decreased the expression of Cx43 protein, resulted in a decrease in CV, but neither a MR blocker nor a GR blocker prevented the decrease in Cx43 expression caused by 10 -6 -10 -4 mol/L aldosterone. This concurs with recent observations by Muto et al that in cultured ventricular myocytes a high concentration of aldosterone (10 -6 mol/L), unlike at a low concentration (10 -8 mol/L), causes a decrease in If and downregulation of HCN2 and HCN4. 22 Mano et al reported that >10 -6 mol/L aldosterone directly induced myocyte apoptosis through calcineurin-dependent pathways. 39 Thus, an extremely high concentration of aldosterone (10 -6 -10 -4 mol/L) might cause myocyte damage, in part through an apoptotic pathway.
In various types of epithelial cells and vascular smooth muscle cells, expression of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) converts endogenous glucocorticoids into their receptor-inactive 11-keto-analogs, thereby conferring aldosterone selectivity on the MR. However, cardiac expression of 11β-HSD2 is extremely low, 46 such that cardiomyocyte MRs are normally occupied by endogenous glucocorticoids that are present at higher levels than aldosterone under physiological conditions. However, in pathophysiological states with high concentrations of aldosterone, it has been reported that mineralocorticoids can access the cardiac MR and affect cardiac protein metabolism. 10 In the present study, we found that Cx43 expression was modulated by 10 -8 -10 -4 mol/L aldosterone. Such a high concentration of aldosterone may be relevant in the context of cardiac hypertrophy, because intracardiac aldosterone levels of 1.6×10 -8 mol/L have been reported in the rat myo-cardium. 3 Moreover, it is reported that the level of aldosterone in plasma is approximately 10 -7 mol/L in patients with heart failure, and that the level of aldosterone in the myocardium is approximately 17-fold higher than that in plasma. 3, 47 Aldosterone and Arrhythmogenesis: Pathophysiological Implications The electrophysiological alterations observed during the development of hypertrophy or heart failure, crucial for arrhythmogenesis, have been extensively reviewed by Tomaselli and Marban. 48 Indeed, aldosterone-induced upregulation of depolarizing INa and ICa, as well as downregulation of K + currents, may all participate in a synergistic manner to prolong the duration of action potentials. 48 Aldosterone-induced upregulation (at low concentrations) and downregulation (at high concentrations) of If is also reported. 22 In addition to this ion channel remodeling, our results indicate that aldosterone-dependent alterations in Cx43 expression, and the subsequent changes in the conduction properties of cardiomyocytes, may also be involved in its potentially proarrhythmic action. Recently, Bian and Tung reported that a structurally heterogeneous form of alteration in CV affects the vulnerability to reentry during rapid pacing. 49 Therefore, effective prevention of aldosterone activation during the development of gap junction remodeling might be, at least in part, an important therapeutic strategy for the treatment of arrhythmias.
Study Limitations
The first is the lack of measurement of action potential upstroke velocities in the mapping system. INa is known to influence cell-to-cell propagation, and Boixel et al recently reported that aldosterone upregulates cardiac INa. 20 Therefore, we could not exclude the effects of upregulated INa on the increase in CV, and further studies are needed to clarify this point. The second limitation is the lack of a functional index of coupling. An important surrogate for cell-to-cell coupling is tissue resistance or effective space constant. In our experiments using neonatal cardiomyocytes, the space constant measurement cannot to be made. In light of this limitation, CV is presented as a viable surrogate for coupling. 28 
Conclusions
The present study reveals that aldosterone affects the expression of gap junction Cx43 through its dual effects on Cx43 expression. Treatment of myocytes by aldosterone at 10 -8 mol/L resulted in upregulation of Cx43 in association with an increase in CV, and this effect was prevented by eplerenone, a MR antagonist. Treatment of the myocytes with aldosterone at 10 -6 -10 -4 mol/L caused downregulation of Cx43 with a decrease in CV, which was not prevented by the MR antagonist. Aldosterone might be involved in arrhythmogenic gap junction remodeling in diseased hearts through its concentration-dependent dual effects on Cx43 expression.
